Intellia Therapeutics, Inc. (NTLA) Institutional Ownership

Ownership Summary

A total of 278 institutions have reported a stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) as of September 2025, according to recent 13F filings with the SEC.

• These investors collectively held 97.9% of the company's total shares outstanding in September 2025, up from 95.2% in June 2025.
• In percentage terms, this reflects as a holdings change of 4.21% quarter on quarter, and a decrease of 0.71% year over year.
• Among the 278 institutional holders of Intellia Therapeutics, 137 added to their stakes while 91 trimmed their positions and 50 held steady.
• This class of investors increased its holdings in Intellia Therapeutics to 105.06Mn shares for the 13F-cycle ending September 2025, up by 4.24Mn shares quarter on quarter, and up 12.59Mn shares year over year.
• With 11.92Mn shares, ARK Investment Management LLC commands the largest institutional position in Intellia Therapeutics as of September 30, 2025, equating to 11.10% of the company.
• Among the most significant buyers of Intellia Therapeutics during September 2025 were Contrarius Group Holdings Ltd (4.34Mn), GOLDMAN SACHS GROUP INC (2.22Mn), MORGAN STANLEY (1.91Mn), D. E. Shaw & Co., Inc. (1.40Mn), JUPITER ASSET MANAGEMENT LTD (1.36Mn).
• Leading sellers of Intellia Therapeutics stock in September 2025 included CITADEL ADVISORS LLC (2.75Mn), ARK Investment Management LLC (1.10Mn), BALYASNY ASSET MANAGEMENT L.P. (1.06Mn), Woodline Partners LP (1.02Mn), Trexquant Investment LP (857.22K).
• The top 10 institutional holders of Intellia Therapeutics for the quarter ending September 2025 included ARK Investment Management LLC (11.92Mn), VANGUARD GROUP INC (11.04Mn), BlackRock, Inc. (9.28Mn), MORGAN STANLEY (6.02Mn), Contrarius Group Holdings Ltd (5.89Mn), STATE STREET CORP (4.97Mn), GOLDMAN SACHS GROUP INC (4.28Mn), REGENERON PHARMACEUTICALS, INC. (3.70Mn), BAKER BROS. ADVISORS LP (2.75Mn), GEODE CAPITAL MANAGEMENT, LLC (2.59Mn).